BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25664920)

  • 21. [Prevalence and transmission of pyrazinamide-resistant
    Liu BB; Hu PL; Chen ZH; Yi SL; Zhang XP; Tan YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jul; 45(7):677-685. PubMed ID: 35768376
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
    BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility.
    Park S; Jo KW; Shim TS
    Int J Tuberc Lung Dis; 2020 Feb; 24(2):233-239. PubMed ID: 32127109
    [No Abstract]   [Full Text] [Related]  

  • 26. [Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey].
    Senol G; Coşkun M; Gündüz AT; Biçmen C; Gayaf M; Ozsöz A
    Mikrobiyol Bul; 2008 Oct; 42(4):591-7. PubMed ID: 19149080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal expansion of Mycobacterium tuberculosis isolates and coexisting drug resistance in patients newly diagnosed with pulmonary tuberculosis in Hanoi, Vietnam.
    Hung NV; Ando H; Thuy TT; Kuwahara T; Hang NT; Sakurada S; Thuong PH; Lien LT; Keicho N
    BMC Res Notes; 2013 Nov; 6():444. PubMed ID: 24188178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960.
    Maslov DA; Zaĭchikova MV; Chernousova LN; Shur KV; Bekker OB; Smirnova TG; Larionova EE; Andreevskaya SN; Zhang Y; Danilenko VN
    Tuberculosis (Edinb); 2015 Sep; 95(5):608-12. PubMed ID: 26071666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.
    Xia Q; Zhao LL; Li F; Fan YM; Chen YY; Wu BB; Liu ZW; Pan AZ; Zhu M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1690-5. PubMed ID: 25583712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative
    Lopez JM; Zimic M; Vallejos K; Sevilla D; Quispe-Carbajal M; Roncal E; Rodríguez J; Rodríguez J; Antiparra R; Arteaga H; Gilman RH; Maruenda H; Sheen P
    J Clin Microbiol; 2023 May; 61(5):e0152222. PubMed ID: 37071032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California.
    Budzik JM; Jarlsberg LG; Higashi J; Grinsdale J; Hopewell PC; Kato-Maeda M; Nahid P
    PLoS One; 2014; 9(4):e95645. PubMed ID: 24759760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
    Walsh KF; Souroutzidis A; Vilbrun SC; Peeples M; Joissaint G; Delva S; Widmann P; Royal G; Pry J; Bang H; Pape JW; Koenig SP
    Am J Trop Med Hyg; 2019 Feb; 100(2):392-398. PubMed ID: 30594266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
    Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
    Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
    Forsman LD; Jonsson J; Wagrell C; Werngren J; Mansjö M; Wijkander M; Groenheit R; Hammar U; Giske CG; Schön T; Bruchfeld J
    Clin Infect Dis; 2019 Sep; 69(8):1394-1402. PubMed ID: 30561569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Characteristics of pncA gene in multidrug-resistant Mycobacterium tuberculosis isolates and its correlation with drug resistance to pyrazinamide].
    Hong CY; Wang F; Gui J; Liu XL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 May; 46(5):436-9. PubMed ID: 22883731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
    Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
    J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A quantitative adaptation of the Wayne test for pyrazinamide resistance.
    Meinzen C; Proaño A; Gilman RH; Caviedes L; Coronel J; Zimic M; Sheen P
    Tuberculosis (Edinb); 2016 Jul; 99():41-46. PubMed ID: 27450003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.